CAR T-cell therapy in diffuse large B-cell lymphoma

SummaryDiffuse large B ‑cell lymphoma (DLBCL) comprises 30–40% of non-Hodgkin’s lymphoma. Clinical factors such as a high International Prognostic Index (IPI) or molecular factors as cell of origin (COO) have an influence on the clinical outcome after conventional immunochemotherapy. Patients with resistant or rela psed (r/r) DLBCL have a poor prognosis with a median overall survival of 6,3 months and low complete response rates (CR 7%) to salvage chemoimmunotherapy. Currently, therapy with autologous chimeric antigen receptor T‑cells (CAR T‑cells) provide encouraging complete responses (CR) of up to 50 %. However, high costs for approved products and elaborate logistics have to be encountered.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research